GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » West Pharmaceutical Services Inc (NYSE:WST) » Definitions » Net Income Including Noncontrolling Interests

WST (West Pharmaceutical Services) Net Income Including Noncontrolling Interests : $467 Mil (TTM As of Mar. 2025)


View and export this data going back to 1973. Start your Free Trial

What is West Pharmaceutical Services Net Income Including Noncontrolling Interests?

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

West Pharmaceutical Services's Net Income Including Noncontrolling Interests for the three months ended in Mar. 2025 was $90 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Mar. 2025 was $467 Mil.


West Pharmaceutical Services Net Income Including Noncontrolling Interests Historical Data

The historical data trend for West Pharmaceutical Services's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

West Pharmaceutical Services Net Income Including Noncontrolling Interests Chart

West Pharmaceutical Services Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Income Including Noncontrolling Interests
Get a 7-Day Free Trial Premium Member Only Premium Member Only 346.20 661.80 585.90 593.40 492.70

West Pharmaceutical Services Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Net Income Including Noncontrolling Interests Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 115.30 111.30 136.00 130.10 89.80

West Pharmaceutical Services Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $467 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


West Pharmaceutical Services Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of West Pharmaceutical Services's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.


West Pharmaceutical Services Business Description

Traded in Other Exchanges
Address
530 Herman O. West Drive, Exton, PA, USA, 19341-1147
West Pharmaceutical Services is based in Pennsylvania, US, and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), non-glass containment solutions, and auto-injectors for injectable drugs, which include large molecule biologics, peptides such as GLP-1 receptor agonists, and small molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
Executives
Charles Witherspoon officer: VP & Treasurer 530 HERMAN O WEST DRIVE, EXTON PA 19341
Eric Mark Green officer: Chief Executive Officer 530 HERMAN O. WEST DRIVE, EXTON PA 19341
Silji Abraham officer: Chief Digital & Trans Officer 5000 TOWN CENTER, U, SOUTHFIELD MI 48075
Thomas W Hofmann director FIVE RADNOR CORPORATE CENTER, SUITE 500, RADNOR PA 19087
Chad Winters officer: VP, CAO & Controller 530 HERMAN O. WEST DRIVE, EXTON PA 19341
Annette F Favorite officer: Sr. VP Human Resources Officer 530 HERMAN O. WEST DRIVE, EXTON PA 19341
Cindy Reiss-clark officer: Senior Vice President 530 HERMAN O. WEST DRIVE, EXTON PA 19341-1147
Quintin J Lai officer: VP Corp Development & Strategy 530 HERMAN 0. WEST DRIVE, EXTON PA 19341
Bernard Birkett officer: Sr VP, CFO & Treasurer 1600 WEST MERIT PARKWAY, SOUTH JORDAN UT 84095
Stephen H Lockhart director C/O NATIONAL RESEARCH CORPORATION, 1245 Q STREET, LINCOLN NE 68508
Molly Joseph director 9209 GRAND SUMMIT BLVD, DRIPPING SPRINGS TX 78620
Kimberly Banks Mackay officer: SVP, GC & Corporate Secretary 530 HERMAN O. WEST DRIVE, EXTON PA 19341
George Lloyd Miller officer: Sr. VP, GC & Corp. Sec. 530 HERMAN O. WEST DRIVE, EXTON PA 19341
David A Montecalvo officer: SVP, Glob Ops and Supply Chain 530 HERMAN O. WEST DRIVE, EXTON PA 19341
Robert F Friel director 940 WINTER STREET, WALTHAM MA 02451

West Pharmaceutical Services Headlines

From GuruFocus